NMLSF (Restart Life Sciences) Moat Score: 2/10 (As of Jun. 29, 2026)


What is Restart Life Sciences Moat Score?

Restart Life Sciences NMLSF -0.23% Moat Score is 2 as of Jun. 29, 2026. The stock has 3 warning signs investors should review. Among 1,401 Biotechnology companies, Restart Life Sciences ranks better than 58.1% on this metric.

Restart Life Sciences has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Restart Life Sciences has No Moat: Restart Life Sciences Corp lacks significant market leadership, network effects, or valuable intellectual property. The company does not exhibit strong brand strength or durable cost advantages, and there are no significant regulatory barriers or exclusive licenses. Its innovation and R&D capabilities are not impactful enough to establish a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Restart Life Sciences might have No Moat - Very weak/transient advantages.

Restart Life Sciences  (OTCPK:NMLSF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Restart Life Sciences Moat Score Related Terms

NMLSF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Restart Life Sciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Restart Life Sciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Restart Life Sciences (NMLSF) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Restart Life Sciences ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Restart Life Sciences' Moat Score too high?
Restart Life Sciences' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Restart Life Sciences' value of 2 is 0% at this industry median. Based on the distribution chart, Restart Life Sciences ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint.
How does Restart Life Sciences' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #587 out of 1401 companies for Moat Score. This puts Restart Life Sciences in the upper half of its industry. The industry median Moat Score is 2.00. Restart Life Sciences' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Restart Life Sciences's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Restart Life Sciences's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (NMLSF) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Restart Life Sciences (NMLSF), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Restart Life Sciences Business Description

Other Exchanges HEAL:Canada
Address 700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.